agreed that conversations about health states took place. Although 53% of patients and surrogates agreed that they had discussed life-sustaining treatment, it is the outcome of treatment and the resultant health states that form the foundation for patients' preferences, as the authors have shown in their earlier work. As they discuss, this may be why agreement about advance directive completion in the 2017 study was not associated with improved surrogate knowledge of patients' preferences, while discussions about patients' valuation of quality vs quantity of life was associated. 6 Another reason for the present findings of Fried et al 5 may
be the well-known psychological phenomenon of overconfidence bias, often seen for tasks that are difficult and for which individuals lack prior experience. 7 As Fried and colleagues point out, 5 overconfidence of potential surrogates may be an important barrier to ACP engagement. Future studies should explore whether surrogates' prior experience with medical decision making may mitigate overconfidence bias. For example, surrogates who have cared for seriously ill or dying patients and have experience making medical decisions for others overwhelmingly agree that ACP is needed. 2 However, because lack of confidence may also be a barrier to ACP, especially among populations with limited health literacy, providing easy-to-understand health information will be important in addition to providing messages tailored to surrogates' readiness to engage in the ACP process. Preparation of surrogates is needed to prevent stress and distrust of the health care system that can have long-lasting effects for that person and their family. 3 In fact, decreasing burden on loved ones can be a strong motivator of patient engagement in ACP. 2 To improve awareness of surrogates' needs, ACP definitions may need to be updated to not only include patient preparation, but also preparation of surrogates for communication and decision making. Furthermore, as many health care organizations and health plans are increasing ACP efforts for patients, many could consider formal inclusion of surrogate preparation in that process. In addition to asking patients about whether they have completed advance directives or named a surrogate decision maker, clinicians can also ask and document whether patients have had discussions with the surrogate about their role and the patient's preferences. times per day in glycemic control, nor evidence of effects on health-related quality of life, patient satisfaction, or decreased number of hypoglycemic episodes. 2 The aim of this study was to quantify the rate of use and cost of selfmonitoring blood glucose supplies that are potentially used inappropriately, specifically focusing on test strips, the most costly supply for regular blood glucose monitoring. Ninth Revision codes 250.X0 or 250.X2 (where X ranges from 0 to 9). Patients were excluded if they received any prescription for insulin. Individuals were followed for at least 1 year after filling a prescription for test strips, or for the calendar year of 2014 if no prescription was filled. Only individuals with 3 or more claims for test strips-suggesting routine use-and those with no claims for test strips within the 1-year study period were included (Table) . University of Michigan Institutional Review Board approval was waived as the data were deidentified. Participant consent was waived as the data were deidentified. All tests were 2-sided and results were deemed statistically significant at P < .05. Discussion | Despite a lack of clinical evidence and being identified as a low-value service by the Choosing Wisely initiative, a substantial percentage of patients with type 2 diabetes may still be inappropriately self-monitoring blood glucose. Nearly 1 in 7 patients with type 2 diabetes not using insulin in this claims database filled 3 or more claims for test strips during the course of 1 year. We acknowledge several limitations within our study. The sample is at risk of bias, as it consists of a selected population with private insurance. Furthermore, we are unable to account for changes in medications or lifestyle as well as transient episodes of hypoglycemia that might warrant monitoring. We also cannot include medications for which a claim was not adjudicated (eg, paying cash for the medication). These limitations notwithstanding, strategies to improve engagement among clinicians and to educate patients are warranted to reduce low-value care. Clinician-facing strategies might include clinical decision support in electronic medical records that create an alert when ordering test strips for patients who are taking nonhypoglycemic medications. Similar tools have reduced inappropriate testing of vitamin D levels. 3 Clinical decision support and interventions such as data feedback, physician communication training, clinician scorecards, and pharmacist review should be aligned with patientcentered strategies such as shared decision making and increased consumer cost sharing (eg, value-based insurance design) to effectively reduce low-value care, while preserving the use of self-monitoring of blood glucose when it is clinically indicated. intellectual conflicts of interest held by some of the panel members involved with the new ACC/AHA guideline, including members who were connected to a major trial that strongly influenced the guideline; and uncertainty regarding blood pressure measurement methods. A checklist-based analysis found that most people newly classified as hypertensive were unlikely to benefit, but instead could experience harms from being unnecessarily labeled as having hypertension, and some people could experience adverse effects from unnecessary medication. 4 We investigated how the media covered the potential benefits and harms of the expanded definition of hypertension.
Methods | We conducted a cross-sectional analysis of media coverage of the expanded definition of hypertension between November 1, 2017, and July 13, 2018. Using explicit terms about guidelines and hypertension, we conducted a broad search of English language stories in the ProQuest database. We also searched ProQuest for press releases and PubMed for journal articles responding to the change. Records were independently screened and were included in the study if they covered the new guidelines or responses to them. Records were excluded if they were duplicates, repeats of news stories syndicated across different outlets, or did not cover the guidelines. A coding tool was developed based on previous media analysis 5 and tools used by organizations, including Health News Review (http://www.healthnewsreview.org), and it was used independently by 2 of us (R.N.M. and L.A.). Discrepancies in screening and coding were resolved by discussion among all authors. Primary outcomes were the proportion of stories covering the expanded definition's potential benefits, potential harms, a balance of benefits and harms, and potential conflicts of interest of members of the ACC/AHA panel. Secondary outcomes included the proportion of stories covering specific evidence supporting the changes, changes to prevalence, costs relating to the changes, uncertainty about blood pressure measurement, and any criticism of the new guideline.
Results | Our searches produced 2309 stories, 932 press releases, and 102 journal articles. After screening and excluding duplicates, syndicated copies, and material not covering the new guidelines, 100 unique stories, 15 press releases, and 37 journal articles were included in the study (a full list of the news stories, press releases, and journal articles is available from the authors). Media coverage was concentrated immediately after publication of the new guidelines in November 2017, with few stories covering subsequent journal articles re- 
